Urology
Volume 71, Issue 5 , Pages 947-951 , May 2008

Etoricoxib and Intermittent Androgen Deprivation Therapy in Patients with Biochemical Progression After Radical Prostatectomy

Received 18 May 2007 ,Accepted 19 September 2007.

References 

  1. Sato N, Gleave M, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol. 1996;58:139–146
  2. Goldenberg SL, Bruchovsky N, Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995;45:839–845
  3. Klotz LH, Herr HW, Morse MJ, et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer. 1986;58:2546–2550
  4. Sciarra A, Di Chiro C, Di Silverio F. Intermittent androgen deprivation in patients with biochemical failure after radical prostatectomy for clinically localized prostate cancer. World J Urol. 2000;18:392–400
  5. Kurek R, Renneberg H, Lubben G, et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol. 1999;35(Suppl):27–31
  6. Tunn UW. Intermittent endocrine therapy of prostate cancer. Eur Urol. 1996;30(Suppl):22–25
  7. Di Silverio F, Gentile V, de Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164–175
  8. Hla T, Bishop D, Liu CH, et al. Cyclooxygenase 1 and 2 isoenzymes. Int J Biochem Cell Biol. 1999;31:551–557
  9. O'Neill GP, Ford AW. Expression of mRNA for cyclooxygenase 1 and 2 in human tissues. FEBS Lett. 1993;330:156–160
  10. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase 2 and prostate carcinogenesis. Cancer Lett. 2003;191:125–135
  11. Kirschenbaum A, Klaisner AP, Lee R, et al. Expression of cyclooxygenase 1 and 2 in human prostate. Urology. 2000;56:671–676
  12. Di Silverio F, Bosman C, Monti S, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:72–78
  13. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpression prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
  14. Smitt MR, Manola J, Kaufman DS, et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006;24:2723–2728
  15. Srinath P, Rao PN, Knaus EE, et al. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res. 2003;23:3923–3928
  16. Pound CR, Partin AW, Eisenberger MA. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  17. Peyromaure M, Delongchamps NB, Debre B, et al. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long term experience. Urology. 2005;65:724–729
  18. Sciarra A, Monti S, Gentile V, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate. 2003;55:168–179
  19. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2005;48:546–551
  20. Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs. 2002;62:2637–2651
  21. Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomized studies of osteoarthritis patients. Ann Rheum Dis. 2007;66:945–951

PII: S0090-4295(07)02167-X

doi: 10.1016/j.urology.2007.09.033

Urology
Volume 71, Issue 5 , Pages 947-951 , May 2008

Article Tools